Ascomycin is a highly valuable multifunctional drug which exhibits numerous biological properties. Being an immunosuppressant, it is known to prevent graft rejection in humans and has potential to treat varying skin ailments. Its derivatives represent a novel class of anti-inflammatory macrolactams. But the biosynthetic machinery of ascomycin is still unclear. Due to the structural complexity, there occurs difficulty in its chemical synthesis; therefore, microbial production has been preferred by using Streptomyces hygroscopicus subsp. ascomyceticus. Through several genetic manipulation and mutagenesis techniques, the yield can be increased by several folds without any difficulties. Genetic engineering has played a significant role in understanding the biosynthetic pathway of ascomycin. Recently, many efforts have been made to utilize the therapeutic effects of ascomycin and its derivatives. This article covers concepts related to the production kinetics of ascomycin including an update of the ongoing yield improvement techniques as well as screening method of novel strains for ascomycin production.

中文翻译：

---

子囊霉素生产的生物过程和基因工程方面：综述


子囊霉素是一种非常有价值的多功能药物，具有多种生物学特性。作为一种免疫抑制剂，它可以预防人类移植排斥，并具有治疗各种皮肤疾病的潜力。其衍生物代表了一类新型的抗炎大环内酰胺。但子囊霉素的生物合成机制仍不清楚。由于结构复杂，其化学合成存在困难；因此，微生物生产优选使用吸水链霉菌亚种。子囊菌。通过多种基因操作和诱变技术，产量可以毫无困难地提高数倍。基因工程在理解子囊霉素的生物合成途径方面发挥了重要作用。最近，人们为利用子囊霉素及其衍生物的治疗作用做出了许多努力。本文涵盖了与子囊霉素生产动力学相关的概念，包括正在进行的产量提高技术的更新以及子囊霉素生产新菌株的筛选方法。